CD274 and breast carcinoma: The KATE2 trial found no benefit of atezolizumab addition in the intent-to-treat population.10 The IMpassion050 trial found no increase in pCR in the intent-to-treat and PD-L1–positive populations.11 The observed discrepancy among efficacy of immunotherapy may be attributed to the difference in antitumor immunity associated with the breast cancer subtype, disease burden, or the partner regimen.